Keyphrases
Hospitalization
100%
Healthcare Utilization
100%
Immune Checkpoint Inhibitors
100%
Steroid-refractory
100%
Immune-related Adverse Events
57%
Ipilimumab
42%
Disease Progression
28%
Poor Prognosis
28%
Monotherapy
28%
Nivolumab
28%
Disease-associated
14%
High Dose
14%
Melanoma
14%
Combination Therapy
14%
Metastatic Melanoma
14%
Disease-related
14%
Dose Escalation
14%
Advanced Melanoma
14%
Median Time
14%
Systemic Steroids
14%
Admission-to-death
14%
Steroid Dose
14%
Vanderbilt University Medical Center
14%
Multiple Hospitalization
14%
Graded Management
14%
Pharmacology, Toxicology and Pharmaceutical Science
Immune Checkpoint Inhibitor
100%
Adverse Event
100%
Synapsin I
100%
Ipilimumab
75%
Disease Exacerbation
50%
Melanoma
50%
Nivolumab
50%
Monotherapy
50%
Diseases
50%
Metastatic Melanoma
25%
Immunosuppressive Agent
25%
Combination Therapy
25%
Immunology and Microbiology
Ipilimumab
100%
Nivolumab
66%
Immunosuppressive Drug
33%
Drug Megadose
33%